• 1
    Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26: 133S136S.
  • 2
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760764.
  • 3
    Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997; 92: 17881792.
  • 4
    Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 13931398.
  • 5
    Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 2096; 334: 16911696.
  • 6
    Martinot-Peignoux M, Boyer N, Cazals-Harem D, Pham BN, Gervais A, Le Breton V, Levy S, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 10001005.
  • 7
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 8
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 9
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 14931499.
  • 10
    Gordon SC, Fang JWS, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32: 400404.
  • 11
    Lee SS, Sherman M. Pilot study of interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 2001; 8: 202205.
  • 12
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis NS, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704707.
  • 13
    Jacobson IM, Russo MW, Lebovics E, Esposito S, Tobias H, Klion F, Brown RS Jr., et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT: final results [Abstract]. Gastroenterology 2002; 122: A-627.
  • 14
    Sponseller C, Koehler KM, Hoffman JA, Strinko JM, Bacon BR. Use of interferon α-2b and ribavirin for treatment of patients with chronic hepatitis C with normal ALT levels [Abstract]. Hepatology 2002; 36: 579A.
  • 15
    Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734739.
  • 16
    Puro V, Petrosillo N, Ippolito G, for the Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Am J Infect Control 1995; 23: 273277.
  • 17
    Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223229.
  • 18
    Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555560.
  • 19
    Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Long-term efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28: 24662473.
  • 20
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562569.
  • 21
    Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199206.
  • 22
    Campistol JM, Esforzado N, Martínez J, Roselló L, Veciana L, Modol J, Casellas J, et al. Efficacy and tolerance of interferon alfa-2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 27042709.
  • 23
    Jefferson JA, Johnson RJ. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000; 20: 286292.